首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C
【24h】

Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C

机译:慢性丙型肝炎患者临床试验的慢性肝病问卷-丙型肝炎(CLDQ-HCV)的性能和验证

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The hepatitis C virus (HCV) infection has tremendous clinical, health-related quality-of-life (HRQOL), and economic burden on patients and the society. To assess the comprehensive impact of HCV infection, systematic tracking of HRQOL in patients with HCV infection is important. Objective: The aim of this study was to systematically validate an HCV-specific HRQOL instrument, the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV), in patients with chronic HCV infection. Methods: The CLDQ-HCV has 29 items in four domains, each scored on a Likert scale of 1-to 7. We used a large cohort of patients with HCV infection enrolled in clinical trials (N = 4142) to test internal consistency, validity, and responsiveness, and we used another cohort of untreated patients with HCV infection (N = 36) to assess test-retest reliability. Results: The CLDQ-HCV performed well in all the psychometric assessments. In particular, the Cronbach alphas ranged from 0.84 to 0.94 for the four domains. The item-to-own-dimension correlations exceeded 0.6 for 27 of the 29 items. Of the clinical and demographic parameters, the presence of cirrhosis and history of psychiatric conditions were discriminated best by the CLDQ-HCV (all P < 0.0001). The domains' correlations with similar domains of the 36-item short form health survey exceeded 0.8. The responsiveness to significant clinical outcomes such as developing treatment-induced anemia and clearance of HCV infection was notable (up to -0.70 for anemia and up to +0.85 for achieving sustained virologic response; all P < 0.0001). Test-retest reliability showed intraclass correlations of 0.84 to 0.93 between multiple administrations. Conclusions: The CLDQ-HCV is a fully validated, simple-to-administer HCVspecific instrument for patients with HCV infection that could be considered in studies of HCV-infected patients.
机译:背景:丙型肝炎病毒(HCV)感染具有巨大的临床,与健康相关的生活质量(HRQOL),并给患者和社会带来经济负担。为了评估HCV感染的综合影响,对HCV感染患者的HRQOL进行系统跟踪非常重要。目的:本研究的目的是系统验证慢性HCV感染患者的HCV特异性HRQOL仪器,即慢性肝病问卷-丙型肝炎(CLDQ-HCV)。方法:CLDQ-HCV在四个领域中有29个项目,每个项目的李克特量表的得分为1到7。我们使用了一大批HCV感染患者参加临床试验(N = 4142),以测试内部一致性,有效性以及反应性,我们使用了另一组未经治疗的HCV感染患者(N = 36)来评估重测信度。结果:CLDQ-HCV在所有心理评估中均表现良好。特别是,四个域的Cronbach alpha范围从0.84到0.94。对于29个项目中的27个,项目与自身维度的相关性超过0.6。在临床和人口统计学参数中,通过CLDQ-HCV可以最佳地区分肝硬化的存在和精神病史(所有P <0.0001)。与36个项目的简短健康状况调查中类似领域的领域相关性超过0.8。对重大临床结局的反应性显着,例如发展为治疗性贫血和清除HCV感染(贫血高达-0.70,实现持续的病毒学反应高达+0.85;所有P <0.0001)。重测信度显示多次给药之间的组内相关性为0.84至0.93。结论:CLDQ-HCV是一种经过充分验证的,易于使用的HCV特异性仪器,可用于HCV感染患者的研究中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号